Objectives: Despite the high prevalence of type 2 diabetes mellitus (T2DM), few data exist describing its management in Dubai. This study characterized the treatment and estimated levels of glycemic, lipid, and blood pressure control among a sample with T2DM at a large Dubai Hospital. Methods: This retrospective cohort study systematically sampled charts from adults seeking care for T2DM from October 2009 to March 2010 until the target (N ¼ 250) was reached. Data on patient characteristics, pharmacotherapy, complications, and laboratory testing were abstracted until September 2011. The frequency of treatments and modifications over the period was calculated, and measures of glycosylated hemoglobin A 1c , lowdensity lipoprotein, and blood pressure control were compared with guideline targets. Frequencies of complications were compared according to treatment type. Results: One-third of the cohort comprised men, and the mean age was 58 years. At enrolment, the mean time from T2DM diagnosis was nearly 15 years and 74% had received insulin. During the study period, the most common regimens were insulin þ oral combinations (55%) and oral combination therapy (39%). Overall, 67% received any insulin therapy during the study; and by study end, 78% had received insulin at any time. At the most recent assessment, guideline targets for glycosylated hemoglobin A 1c , blood pressure, and low-density lipoprotein were met by 23%, 29%, and 71%, respectively. Complications were more frequent among those treated with combination or insulin therapies. Conclusions: This study provides baseline data from Dubai for future comparisons of the effectiveness of new treatments, and to better understand the humanistic and economic burden of T2DM and its complications.
Introduction
Type 2 diabetes mellitus (T2DM) is a growing health problem worldwide, with incidence rates increasing in both developed and developing countries [1] . In the United Arab Emirates (UAE), the occurrence of T2DM has risen dramatically in recent years and its population now has among the highest prevalence of T2DM globally, with 19% to 25% of the population affected [2, 3] . In addition to the enormous epidemiologic burden, the economic burden associated with the treatment and management of T2DM is substantial; it is estimated that 7% to 13% of global health care budgets will be spent on managing diabetes and its complications by the year 2025 [1] . In countries with high prevalences, this figure may be as high as 40% [1] .
A major contributor to the clinical and economic burden of T2DM is the management of its associated complications, both macrovascular (i.e., cardiovascular disease) and microvascular (i. e., retinopathy, nephropathy, neuropathy, and diabetic foot) [4] . The risk of developing macrovascular and microvascular complications is increased among persons with T2DM who have poor lipid, blood pressure, and in particular glycemic control [5] . Accordingly, meeting target levels on these measures, defined in both the American Diabetes Association (ADA) [5] and the UAE National Diabetes Guidelines [6] , are key goals for the management of persons with T2DM.
Much information has been published on treatment practices and achievement of treatment targets among persons with T2DM in the United States and other developed countries where T2DM has been a long-standing public health concern. Despite the growing epidemiologic and economic burden of T2DM in the UAE, little is known about how persons with T2DM are managed in clinical practice and the frequency of attainment of guideline targets for glycemic, lipid, and blood pressure control [7] [8] [9] .
Documenting existing treatment patterns and treatment target success is important to provide baseline information by which to evaluate new treatments and disease management practices and to track changes in measures of disease control and the economic burden over time.
We undertook a retrospective observational study to quantitatively characterize contemporary treatment patterns and measures of treatment success among persons with T2DM in Dubai, UAE. The primary objective here was to characterize treatment patterns according to treatment modality and to estimate the proportion of subjects successfully controlling blood glucose, lipid, and blood pressure levels between 2009 and 2011 among persons being managed for T2DM in Dubai, UAE. Secondary objectives were to 1) estimate the impact of age, sex, duration of T2DM, and therapy type on the proportion of subjects meeting guideline targets; 2) describe treatment modifications according to the duration of T2DM and previous therapy use; and 3) measure the frequency of microvascular and macrovascular complications.
Methods
This retrospective cohort study was conducted among a sample of persons with T2DM who were being managed at a single diabetes outpatient clinic operating in the Dubai Hospital in Dubai, UAE; this secondary and tertiary care hospital is the largest general medical and surgical hospital in the emirate of Dubai.
Subjects
The target population was persons being treated for T2DM in Dubai, UAE. To be eligible for inclusion, subjects were required to have a diagnosis of T2DM according to ADA criteria [5] , be 18 years of age or older, and of UAE nationality. Subjects enrolled in clinical trials and women who were pregnant during the study period were not eligible.
Electronic medical records of persons with T2DM were identified by International Classification of Diseases, Ninth Revision codes (250.x0, 250.x2), and a random sample was systematically included by selecting every nth chart from the Dubai Hospital database, which contained records for the more than 5000 persons managed at the hospital's diabetes clinic. Medical charts identified from the database were then screened for eligibility on the basis of subjects attending physician visits at the study site during the 6-month study enrolment period (October 1, 2009, to March 3, 2010) . Systematic sampling and eligibility screening continued until the target number of 250 eligible charts was reached.
Because the Dubai Hospital is a secondary and tertiary care center, subjects may have been initially diagnosed at the study site or referred from another clinical site; the study sample would therefore represent a mix of subjects more recently diagnosed with T2DM and those with long-standing disease.
The study protocol was approved by the Research Ethical Approval Committee at the Dubai Hospital.
Study Period
Data were collected on treatments and outcomes from all eligible subjects during the follow-up period, which ended September 30, 2011. Eligible subjects had to visit the study site during the enrolment period, from October 1, 2009 , to March 31, 2010 . This allowed a minimum of 18-month follow-up for subjects enrolled at the end of the enrolment period. The study enrolment date was defined as a subject's most recent visit to the study site during the accrual period.
Data Collected
The following data were abstracted from the paper copies of charts of eligible subjects: 1) demographic and clinical characteristics from the time of T2DM diagnosis and at study enrolment; for those not diagnosed at the study site, time of diagnosis was based on reports from the referring physician; 2) types of pharmacotherapy (i.e., treatments) administered before study enrolment and the type, dosage, and timing of treatments administered between study enrolment and censoring (September 30, 2011); 3) the presence of microvascular (retinopathy, peripheral neuropathy, nephropathy, chronic kidney disease, and diabetic foot) or macrovascular (angina, previous stroke/ transient ischemic attack, coronary artery disease, peripheral vascular disease, myocardial infarction, and congestive heart failure) complications at study enrolment and during the study period; and 4) results of glycosylated hemoglobin (Hb A 1c ), lowdensity lipoprotein (LDL), blood pressure, high-density lipoprotein, triglyceride, and total cholesterol tests from the time of study enrolment to censoring.
Treatment types were classified as oral monotherapy, oral combination therapy, insulin monotherapy, insulin combination therapy, or insulin plus oral combination therapy. Treatment regimens were defined as the unique combination of specific drugs (including metformin, glibenclamide, gliclazide, glimepiride, rosiglitazone, pioglitazone, acarbose, miglitol, repaglinide, nateglinide, exenatide, sitagliptin, vildagliptin, or insulin); changes in treatment were defined as either regimen changes (change in treatment regimen through the replacement, removal, or addition of drugs) or regimen modification (defined as a change in the dose of an existing treatment regimen).
Data collection was performed by two trained data abstractors. No subject identifiers were abstracted from the charts, and a unique identifier was assigned for each subject. All case report forms were checked for completeness, and those with missing data were checked against the source data. At least 50% of the case report forms completed by each abstractor per day were checked against the source data; if discordance between the abstractors was more than 20%, all case report forms completed that day were validated against the source data.
Sample Size
Sample size calculations were based on the ability of the study to detect treatments and events of prespecified frequencies. The target sample size of 250 had a 92% chance of detecting treatments or events occurring with a 1% frequency and a 100% chance of detecting treatments or events occurring with more than 5% frequency [10] .
Analysis
Descriptive statistics were generated for baseline characteristics at study enrolment including age, sex, T2DM duration (time from diagnosis date to study enrolment date), site of T2DM diagnosis, immediate relatives with T2DM, Hb A 1c level of less than 7%, previous T2DM treatments (prescriptions documented in the
chart before enrolment date), and presence of microvascular and macrovascular complications (diagnosis documented in subject chart before or at study enrolment date).
Types of treatment regimens, their frequency of use, as well as the number of treatment modifications (either drug change [replacement, removal, or addition] or dose change) over the study period were calculated and were stratified by T2DM duration and previous treatment at enrolment. Treatment types were classified as oral monotherapy (e.g., metformin, a sulfonylurea, thiazolidinedione, meglitinide, alpha-glucosidase inhibitor, or dipeptidyl peptidase 4 inhibitor); oral combination therapy (two or more oral medications used in combination); insulin monotherapy (one type of insulin, used alone); insulin combination therapy (two or more types of insulin used in combination); or insulin plus oral combination therapy (one or more types of insulin used in combination with one or more oral medications). Subjects may have been treated with more than one treatment type over the study period.
Levels of glycemic, lipid, and blood pressure control were calculated from the first and last measurements during the study period. The percentages of subjects meeting ADA and UAE National Diabetes Guidelines [5, 6] target levels for Hb A 1c (o7%), LDL (o100 mg/dL), and blood pressure (o130/80 mm Hg) tests were calculated and stratified by sex, age, T2DM duration, and therapy type (categorized as insulin-treated or non-insulintreated on the basis of the most recent T2DM therapy regimen in the study period). Poor glycemic control was defined as an Hb A 1c level of 9% or more; hypertension was defined as systolic blood pressure of 140 mm Hg or more and/or diastolic blood pressure of 90 mm Hg or more.
The number and percentage of subjects achieving differing levels of control on Hb A 1c , LDL, and blood pressure tests, from enrolment to censoring, were calculated and stratified by T2DM duration and by treatment type during the study period. Levels of control were categorized as well controlled (target met on 100% of the tests), partially controlled (target met on 50% of the tests), or never controlled (target met on 0% of the tests).
Frequencies of microvascular and macrovascular complications, during the study period and at study end, were calculated and compared using the chi-square test according to treatment type at the beginning and end of the study period. The number and percentage of subjects achieving differing levels of control on Hb A 1c , LDL, and blood pressure tests, from enrolment to censoring, were also calculated and stratified by complication status at the end of the study period.
Results
A total of 422 T2DM charts were screened, of which 250 (59%) were from eligible subjects with T2DM. The most common reasons for ineligibility were that the subject did not visit the study site during the enrolment period (50% of the excluded subjects) or did not have a confirmed diagnosis of T2DM according to ADA criteria (41%). Among the 250 eligible subjects, onethird were men, mean age at enrolment was 58 Ϯ 12 years, and mean time from T2DM diagnosis was nearly 15 years (Table 1) . Baseline characteristics stratified by previous treatment type are presented in Appendix Table 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2015.08.006. The duration of T2DM was longer, and the frequency of complications at baseline higher, among those previously treated with insulin than among those who were insulin naive.
Treatment Patterns
At study enrolment, the most common previous treatments included metformin, insulin, and sulfonylureas, which were used by 58% to 85% of the subjects (Table 2 ). More subjects with longstanding (Z20 years) T2DM had previously received insulin therapy than did those recently diagnosed (o5 years) with T2DM (83% vs. 55%, respectively). During the study period, more than half of the subjects were treated with insulin plus oral combination therapy and nearly 40% received oral combination therapy. Two-third of the subjects received any insulin therapy, and nearly twice as many subjects with long-standing T2DM were treated with insulin compared with those with newly diagnosed T2DM.
By study end, approximately three-quarter of the subjects had received insulin therapy at any time, either before or during the study period. Most subjects underwent a modification to their treatment regimen during the minimum 18 months of follow-up per subject (92%; data not shown). On average, subjects with T2DM had one drug change and nearly three drug or dose changes over the study period (Table 2) . Little variation was seen by T2DM duration. Data on treatments prescribed and treatment modifications, stratified by previous treatment type, are [5, 6] . ‡ Therapies used alone or in combination with other agents. 
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T2DM Control and Treatment Target Success
Overall, levels of LDL control were high, with nearly three-quarter of the subjects meeting guideline targets; levels of blood pressure and glycemic control were lower, with less than one-third of the subjects meeting targets (Table 3) . Still, modest improvements were seen in the percentage of subjects meeting guideline targets for Hb A 1c and LDL over the study period. Conversely, nearly half of the subjects had hypertension at study end, and approximately one-quarter of the subjects had poor glycemic control. Levels of HDL, triglycerides, and total cholesterol at the first and last measurements during the study period are presented, stratified by T2DM duration, in Appendix The percentage of subjects with T2DM meeting guideline targets for Hb A 1c , LDL, and blood pressure at the most recent assessment during the study period was similar between men and women and across age categories (see Appendix  Fig. 1A ,B in Supplemental Materials found at http://dx.doi.org/ 10.1016/j.vhri.2015.08.006). More non-insulin-treated subjects met guideline targets for Hb A 1c , LDL, and blood pressure than did insulin-treated subjects, particularly for Hb A 1c (47% vs. 11%, respectively) (see Appendix Fig. 1C ). There was little variation in achievement of LDL and blood pressure targets across T2DM duration categories; however, the percentage of subjects meeting Hb A 1c targets decreased as the T2DM duration increased, from 31% among newly diagnosed subjects to 10% among those with long-standing T2DM (Table 3 ; see Appendix Fig. 1D ).
Complications
The number of subjects with reported microvascular (n ¼ 41 [16.4%]) or macrovascular (n ¼ 18 [7.2%]) complications at study enrolment was low; during the study period, four (1.6%) subjects Note. Values are n (%) unless indicated otherwise. IQR ¼ interquartile range; T2DM, type 2 diabetes mellitus. *Subjects may have received more than one type of treatment during the study period. † Where insulin is listed more than once, it indicates that two different forms of insulin were used.
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with T2DM developed macrovascular complications and seven (2.8%) developed microvascular complications. At study end, a total of 22 (8.8%) subjects with T2DM had experienced macrovascular complications, including angina (4.4%), stroke or transient ischemic attack (1.6%), myocardial infarction (1.2%), coronary artery disease (1.2%), and peripheral vascular disease (1.2%). Microvascular complications were diagnosed in 46 (18.4%) subjects with T2DM by study end, and included retinopathy (8.4%), nephropathy (6.8%), peripheral neuropathy (2.4%), chronic kidney disease (5.6%), and diabetic foot (1.6%). As expected, the occurrence of microvascular or macrovascular complications was more frequent among those treated with combination or insulin therapies (see Appendix Table 6 in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2015.08.006). Although the proportions of subjects achieving Hb A 1c control was similar between those with and without complications, more subjects without complications achieved better blood pressure control, whereas more subjects experiencing complications had better LDL control (see Appendix Table 7 in Supplemental Materials found at http:// dx.doi.org/10.1016/j.vhri.2015.08.006).
Discussion
T2DM is a substantial and growing health problem both globally and in the UAE, which now has among the highest prevalence of T2DM in the world. Despite the considerable clinical and economic burden associated with the disease, little is known about how persons with T2DM in the UAE are managed in clinical practice or the frequency with which they attain guideline targets for glycemic, lipid, and blood pressure control. In this retrospective study, insulin was the most common treatment choice for managing those with T2DM, most frequently in conjunction with oral combination therapy; modifications were regularly attempted to improve T2DM control, and there were modest improvements in the percentage of subjects meeting glycemic and lipid control targets from study start to study end. Overall, levels of control for LDL were good, whereas levels of blood pressure and glycemic control were less so. There was a trend toward decreasing glycemic control with increasing disease duration. This retrospective cohort study is the first to characterize contemporary treatment patterns and levels of treatment target success among persons with T2DM in Dubai. Until very recently, there has been a paucity of published observational studies describing these outcomes among subjects with T2DM in the UAE and the Middle East region although some local evidence is now available. Nearly all published studies have been conducted in the emirate of Abu Dhabi, and the reported percentage of persons with T2DM meeting guideline treatment targets, however, has varied. Two recent studies from the UAE-one crosssectional and one prospective-reported that 35% to 40% of the subjects with diabetes were treated with insulin. Although insulin use was more frequent in the present study, there were notable differences in the sociodemographic and clinical characteristics of the study populations, including T2DM duration, which may limit the comparability [7, 11] . Overall, these findings support the expectation that persons with long-standing T2DM would be more likely to receive treatment with insulin than do those with newly diagnosed T2DM.
Three studies reported that guideline Hb A 1c targets were met by 33% to 45% of the subjects with diabetes in Abu Dhabi and blood pressure targets by 42% to 83% of the subjects [8, 9, 12] . One study reported that LDL targets were achieved by 70% of the subjects [8] . Glycemic and blood pressure control rates were higher than in the present study, and LDL control rates were 
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similar; however, trends in the relative frequency of treatment target success between the different measures were consistent with the present study.
Among these studies and the present study, there were differences in the sociodemographic and clinical characteristics of the samples, the study setting (i.e., hospital vs. populationbased), and the criteria by which subjects with T2DM were identified (i.e., physician diagnosis vs. self-report), which may account for some of the variation seen between studies. The components and location of diabetic care were also found to be an important determinant of diabetic control in a study from primary health care centers with chronic disease clinics in Al Ain, UAE [13] . This finding is of interest because in a separate study of the present cohort of patients, we found that quality of care received was not a significant predictor of whether an individual would meet treatment targets. These discrepant findings could reflect a difference in patterns of care between primary, and secondary or tertiary, health care centers [14] .
The results of the present study extend upon the existing evidence by describing treatment patterns and levels of treatment target success among persons managed for T2DM in Dubai. An important additional consideration for diabetes care in the UAE, which was not easily addressed with the design of the present study, is the impact of fasting during Ramadan on clinical outcomes. Modification of diabetic treatment regimens during Ramadan is common, occurring in 30% to 50% of the patients. How fasting and related treatment modifications impact the ability to achieve treatment targets, however, remains unclear [15] . Understanding rates of achieving guidelines targets is important because treating to target has been demonstrated to help reduce the humanistic and economic burden associated with T2DM and its complications [16] .
This study collected real-world data on contemporary treatment patterns and attainment of guideline treatment targets among a sample of persons with T2DM managed at a diabetes outpatient clinic in a large hospital in Dubai. At the time of study initiation, the sample size of 250 subjects was larger than in other published observational studies of T2DM that had been conducted in the UAE. Although the results of a few studies from the UAE with similar or larger sample sizes are now becoming available [7, 8] , none was conducted in Dubai. Strengths of the present study were the implementation of standardized procedures for data collection and analysis; training of data abstractors to ensure consistent methodology; and implementation of quality checks to ensure data completeness, quality, and consistency between reviewers. Extracted data were checked daily between abstractors and against source data to resolve outstanding issues.
There are several potential limitations of the present study. First, by including only one urban study site, the results of this study may not be representative of the experiences of all persons with T2DM in the UAE, particularly those from rural settings. The Dubai Hospital, however, is the largest general medical and surgical hospital in the emirate of Dubai, and it is likely that this study would capture a range of treatments that are generally representative of treatment options for persons with T2DM in Dubai. Second, the study population had long-standing T2DM and nearly three-quarter of the subjects were diagnosed more than 10 years before study start. Hence, findings from this study may not be generalizable to those with a more recent diagnosis of T2DM. Persons with newly diagnosed T2DM, particularly those not managed at a tertiary care center, may have less severe disease and higher rates of glycemic, lipid, and blood pressure control; therefore, the findings of this study may overestimate the burden of T2DM. Third, we required that subjects had an International Classification of Diseases, Ninth Revision diagnosis code for diabetes as well as met the ADA diagnostic criteria, to increase the homogeneity of the sample and to ensure that persons with type 1 diabetes were not included. Imposing this restriction, however, may have excluded persons with newly diagnosed T2DM or those with less severe disease who did not meet these thresholds.
To our knowledge, this study is the first to describe contemporary treatment patterns and levels of treatment target success among persons managed for T2DM in Dubai. Given the increased risk of developing macrovascular and microvascular complications associated with poor glycemic, lipid, and blood pressure control, higher rates of persons with T2DM meeting guideline targets for these measures, glycemic control in particular, have the potential to reduce the humanistic and economic burden associated with T2DM and its complications in the UAE. Evaluating similar outcomes among primary care centers in Dubai, and in other jurisdictions in the area, would be important to better understand overall treatment patterns and clinical outcomes among those with T2DM in the Arabian Gulf. Novel therapies have the potential to improve T2DM control among persons with T2DM, and this study provides valuable baseline data with which to compare the effectiveness of new T2DM treatments in Dubai, UAE.
